| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner | Director
3 companies
Hudson Executive Capital LP last filed a Form 4 in February 2024, as 10% Owner at TALK. The filings on record cover 3 companies. From August 2019 to February 2023, the filings on record show 7 open-market purchases and 8 sales.
Our model assigns Hudson Executive Capital LP a below-average insider score of 49/100, based on 10 past trades. Over a 12-month horizon, 30.0% of those trades were profitable, with an average 12-month return of -25.9%.
At the last filing, the largest reported position was 17,980,600 shares of TALK. Net of sales, the TALK filings show accumulation of 190,600 shares.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2019 | CTLP Cantaloupe, Inc. | 10% Owner | Buy | 1,801,000 | $4.58 | $8,245,238.60 | +21.6% | |
| Sep 23, 2019 | CTLP Cantaloupe, Inc. | 10% Owner | Buy | 143,200 | $4.46 | $638,672.00 | +1.7% | |
| Sep 17, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 100 | $60.00 | $6,000.00 | - | |
| Sep 12, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 1,312 | $60.06 | $78,798.94 | -0.2% | |
| Aug 1, 2019 | CTLP Cantaloupe, Inc. | 10% Owner | Buy | 1,000,252 | $6.93 | $6,931,746.36 | +13.9% |